固体瘤的中心推进废弃性辐射疗法:单臂II期试验 (CBART) 的研究协议
Lingong Jiang1, Yangsen Cao1, Xiaolan Yin2
1Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Technology in cancer research & treatment
|June 12, 2025
概括
中心增强除性辐射疗法 (CBART) 为大型或与胃肠道相邻的瘤提供了一种新的方法. 这种技术旨在通过向瘤核心输送消毒剂量,同时节省边缘,从而改善局部控制.
科学领域:
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
- 临床瘤学临床瘤学
背景情况:
- 立体体辐射疗法 (SBRT) 对于晚期瘤是常见的,但对于大型或与胃肠道相邻的瘤来说,降解剂量可能是有问题的.
- 正在探索部分辐射策略来管理这些复杂的病例.
- 中心增强除性辐射疗法 (CBART) 是为了向瘤中心提供更高的剂量,同时在边缘保持更低的剂量而开发的.
研究的目的:
- 为了评估CBART在患有大型瘤或瘤邻胃肠道的患者中的疗效.
- 作为主要结果,评估一年的当地控制率.
主要方法:
- 进行了一项前性单臂II期试验.
- 患者接受CBART,其中中央核心GTV (cGTV) 占GTV的50%,以及围绕GTV的2-5毫米边缘的计划目标体积 (PTV).
- 处方剂量为30-45 Gy/5f到瘤边缘和120%-150%的边缘剂量到cGTV,PTV和cGTV的覆盖率为90%.
主要成果:
- 该研究的目的是确定一年的当地控制率.
- 随后,根据瘤特征进行了系统治疗.
结论:
- 通过向缺氧核心提供消化剂量和向边缘提供较低剂量,CBART可以增强对大型或胃肠邻近瘤的局部控制.
- 需要进一步的研究来证实CBART的临床益处.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...